

24th International Thyroid Cancer Survivors' Conference
October 22-24, 2021
Conference Schedule, as of October 22, 2021

Friday, October 22, 2021

- All program times are EDT (New York City time)
- Check out our online auction, www.thyca.org/auction
- Your feedback is important! Please fill out the session evaluation survey at the end of each session.

10:00 – 11:00 a.m. EDT

101 Roundtable: If you're new to thyroid cancer – things to know and questions to ask.

Barb Allhoff, ThyCa Volunteer. [N]

102 Roundtable: If this is your first conference – things to know and questions to ask.

Abby Melendez, ThyCa Volunteer.

103 Get "schooled": Educational accommodations and advocacy for children diagnosed with thyroid cancer. Pam Mendenhall, LISW, ThyCa Pediatric Support Moderator. [Ped]

104 A discussion of novel systemic therapies in thyroid cancer.

Kate Newbold, MB, ChB, MRCP, FRCR, FRCPE. Clinical Oncologist. [Adv,M,SR]

105 Caregivers roundtable. Miguel Melendez, ThyCa Volunteer.

11:10 – 11:20 a.m. EDT

116 Welcome and announcements.

Gary Bloom, ThyCa Executive Director; and Howard Solomon, ThyCa Board Chair.

11:30 a.m. – 12:30 p.m. EDT

121 Getting to know each other: Open-microphone roundtables. ThyCa Volunteers.

123 Medullary thyroid cancer roundtable: Getting to know each other – Part 1. Bill McClain and Kelley Pratt, ThyCa Volunteers. [M]

124 Anaplastic thyroid cancer roundtable: Getting to know each other. Cheri Lindle, MEd, ThyCa Volunteer. [A]

125 Poorly differentiated thyroid cancer roundtable: Getting to know each other. Julie Martwick, ThyCa Volunteer.

1:00 – 2:00 p.m. EDT

131 The ABCs of thyroid cancer: Understanding key terms, concepts, and initial diagnostic and treatment steps. Lindsay A. Bischoff, MD, Endocrinologist. [N,SR]

132 Patient decision-making in low-risk papillary thyroid cancer, including active surveillance.

Louise Davies, MD, MS, FACS, Otolaryngologist; Anna Sawka, MD, PhD, Endocrinologist; and R. Michael Tuttle, MD, Endocrinologist. [AYA,N,Ped,PF,SR]

133 Medullary thyroid cancer roundtable: Getting to know each other – Part 2. Bill McClain, Bill Nelson, and Kelley Pratt, ThyCa Volunteers. [M]

134 Contemporary surgical treatment of differentiated (papillary and follicular) thyroid cancer and recurrent thyroid cancer. Gary L. Clayman, DMD, MD, FACS, Thyroid Cancer Surgeon. [Adv,AYA,H,N,Ped,PF,SR]

135 A general discussion on radioactive iodine, when to use it, and how much to use.

Erik Mittra, MD, PhD, Nuclear Medicine Physician. [Adv,AYA,H,N,Ped,PF,SR]

Session Key (You are welcome to attend any session.)

A: Anaplastic	Adv: Advanced Disease	AYA: Adolescent/Young Adult	H: Hurthle Cell	M: Medullary
N: Newly Diagnosed	Ped: Pediatric	PF: Papillary/Follicular	SR: Session to be Recorded	

Friday, October 22, 2:30 – 3:30 p.m. EDT

141 Your mouth, salivary glands, and teeth: Preventing and solving issues caused by treatments, including radioactive iodine or external beam radiation.

Mark S Chambers, DMD, MS, Oral Medicine Specialist. [SR]

142 Roundtable: How do I meditate anyway? Using mindful meditation for stress relief.

Roberta Perry, ThyCa volunteer.

143 Medullary thyroid cancer: Medical management at the beginning of the journey.

Naifa L. Busaidy, MD, Endocrinologist; and Elizabeth G. Grubbs, MD, Surgeon. [M,SR]

144 Update on the management of anaplastic thyroid cancer.

Maria E. Cabanillas, MD, Oncologic Endocrinologist. [A,SR]

145 Haga sus preguntas a la médica en español. Laura Boucai, MD, Endocrinólogo. [SR]

4:00 – 5:00 p.m. EDT

151 Panel: Am I a candidate for less-invasive treatment? A discussion about percutaneous alcohol ablation, radiofrequency ablation, and scarless surgery.

Moderator: Mark L. Urken, MD, FACS, FACE, Otolaryngologist.

Panelists: Victor J. Bernet, MD, Endocrinologist; Jennifer L. Holkem, Patient Advocate; and Jonathan O. Russell, MD, Thyroid Surgeon. [Adv,AYA,H,M,N,PF,SR]

152 Radioiodine refractory (non-avid, RAI resistant) thyroid cancer. Novel redifferentiation therapies. Laura Boucai, MD, Endocrinologist. [Adv,AYA,H,PF,SR]

153 Somatostatin receptor based therapy in medullary thyroid cancer.

Herbert Chen, MD, FACS, Endocrine Surgeon. [M,SR]

154 Monitoring of low and intermediate risk papillary and follicular thyroid cancer patients in the first five years after initial treatment(s). Stephanie Fish, MD, Endocrinologist. [AYA,Ped,PF,SR]

155 Patient-reported outcomes after thyroid surgery. What others report about complications, side effects, and worry. Megan R. Haymart, MD, Endocrinologist. [SR]

5:30 – 6:30 p.m. EDT

161 Redifferentiation: An ongoing trial. Alan L. Ho, MD, Oncologist. [Adv,AYA,H,PF,SR]

162 An individualized approach to thyroid hormone replacement for thyroid cancer patients.

Kaniksha Desai, MD, ECNU, Endocrinologist. [SR]

163 Medullary thyroid cancer: Targeted therapy before and/or after surgery.

Mark E. Zafereo, MD, Head and Neck Surgeon. [M,SR]

164 A discussion about the updated anaplastic thyroid cancer guidelines.

Electron Kebebew, MD, FACS, Endocrine Surgeon. [A,SR]

165 Navigating health insurance; Trying to figure out how to pick a health insurance plan that actually covers your medical expenses? This session will explain your health insurance options, current laws regarding pre-existing conditions and other consumer protections, how to pick a plan that works for you, and how to get financial assistance to help you pay for health insurance.

Monica Fawzy Bryant, Esq, Attorney. [SR]

Session Key (You are welcome to attend any session.)

A: Anaplastic	Adv: Advanced Disease	AYA: Adolescent/Young Adult	H: Hurthle Cell	M: Medullary
N: Newly Diagnosed	Ped: Pediatric	PF: Papillary/Follicular	SR: Session to be Recorded	

Friday, October 22, 7:00 – 8:30 p.m. EDT

171 Young adults virtual meet-up. For people ages 18 to 40.

Aime T. Franco, PhD, AYA Cancer Survivor. [AYA]

172 Virtual anaplastic thyroid cancer meet-up. Patti Turner, ThyCa Volunteer. [A]

173 “Meddie” (medullary thyroid cancer) virtual meet-up. Bill McClain, ThyCa Volunteer. [M]

174 Thyroid cancer and the importance of first-person narratives. The filmmaker will walk participants through her creative process of producing a documentary film about her treatment for papillary thyroid cancer. The session will center the patients' perspective and how it is represented or excluded from film and TV. Participants will be invited to share their own experiences and thoughts on the subject. *What would representation in TV/film look like for you? How have you maintained/discovered/rewritten your own personal narrative since your diagnosis?*

Bryn Silverman, Filmmaker and Thyroid Cancer Survivor.

7:30 – 8:30 p.m. EDT

185 Update on trials for thyroid cancer in Australia. Bruce Robinson, MD, Endocrinologist.

[A,Adv,AYA,M,PF,SR]

9:00 – 10:00 p.m. EDT

191 Radioactive iodine use in the management of patients with thyroid cancer.

Monica Rossleigh, MD, Nuclear Medicine Physician. [Adv,AYA,H,Ped,PF,SR]

RECORDINGS

501 Discussione sul cancro alla tiroide in italiano. La diagnosi preoperatoria del nodulo tiroideo maligno. Cosimo Durante, MD, Endocrinologo. [SR]

503 Discussione sul cancro alla tiroide in italiano. La terapia e il follow-up del cancro della tiroide. Laura Fugazzola, MD, Endocrinologo. [SR]

511 日本における甲状腺癌マネジメントのオーバービュー。 Part 1: Thyroid nodules 「甲状腺に結節が見つかったら」 (20分) 杉谷 巖、MD、PhD、内分泌外科医 [SR]

512 日本における甲状腺癌マネジメントのオーバービュー。 Part 2: Benign/follicular tumor 「良性/濾胞性腫瘍の場合」 (12分) 杉谷 巖、MD、PhD、内分泌外科医 [SR]

513 日本における甲状腺癌マネジメントのオーバービュー。 Part 3: Papillary thyroid carcinoma 「乳頭癌と診断された場合」 (30分) 杉谷 巖、MD、PhD、内分泌外科医 [SR]

514 日本における甲状腺癌マネジメントのオーバービュー。 Part 4: Anaplastic/ medullary thyroid carcinoma 「未分化癌、髄様癌と診断された場合」 (20分) 杉谷 巖、MD、PhD、内分泌外科医 [SR]

Session Key (You are welcome to attend any session.)

A: Anaplastic	Adv: Advanced Disease	AYA: Adolescent/Young Adult	H: Hurthle Cell	M: Medullary
N: Newly Diagnosed	Ped: Pediatric	PF: Papillary/Follicular	SR: Session to be Recorded	

Saturday, October 23, 2021

- All program times are EDT (New York City time)
- Check out our online auction, www.thyca.org/auction
- Your feedback is important! Please fill out the session evaluation survey at the end of each session.

8:30 – 9:30 a.m. EDT

- 201 Discussion about thyroid nodules and pathological diagnosis, and types of thyroid tumors and pathological features.** Zubair W. Baloch, MD, PhD, Pathologist. [Adv,AYA,H,Ped,PF,SR]
- 202 Improving communication between doctors and thyroid cancer patients: Would a decision aid help?** Vaninder K. Dhillon, MD, FACS, Otolaryngologist. [SR]
- 203 Navigating access to systemic therapy for advanced thyroid cancer in Canada.** Monika K. Krzyzanowska, MD, MPH, FRCPC, FASCO, Medical Oncologist. [Adv,AYA,H,M,Ped,PF,SR]
- 204 International Thyroid Oncology Group: An introduction.** *This session will begin at 9 a.m.* Gregory W. Randolph, MD, FACS, FACE. [SR]
- 205 Thyroid cancer survivorship and what it means to you.** Anjali Kapoor-Davis and Brandee Rockett, ThyCa Volunteers.

10:00 – 11:00 a.m. EDT

- 211 Genetic testing for inherited syndromes in newly diagnosed non-medullary thyroid cancer in young patients including PTEN and DICER1 related syndromes.** Yuri E. Nikiforov, MD, PhD, Pathologist. [Adv,AYA,N,Ped,PF,SR]
- 212 Roundtable: Let's talk about receiving a thyroid cancer diagnosis.** Batya Reckson, LCSW-R, Oncology Social Worker.
- 213 Medullary thyroid cancer roundtable: Including MEN2.** Michelle Perkins, LCSW. [M]
- 214 HypoPara: An unexpected complication after thyroid cancer surgery.** This session is for patients who suffer from hypoPARathyroidism and have difficulty maintaining their serum calcium level after having their thyroid removed. Ryan Polly, PhD, MED; Chrissy Bonatch and Cece Donoghue, ThyCa Volunteers.
- 215 Discussion with a doctor about anaplastic thyroid cancer and Hurthle cell thyroid cancer. What's new?** Jochen J. Lorch, MD, MSc, Medical Oncologist. [A,Adv,H,SR]

11:10 – 11:20 a.m. EDT

- 226 Welcome and announcements.** Gary Bloom, ThyCa Executive Director; and Anita Hubbard, ThyCa Board Member.

Session Key (You are welcome to attend any session.)

A: Anaplastic	Adv: Advanced Disease	AYA: Adolescent/Young Adult	H: Hurthle Cell	M: Medullary
N: Newly Diagnosed	Ped: Pediatric	PF: Papillary/Follicular	SR: Session to be Recorded	

Saturday, October 23, 11:30 a.m. – 12:30 p.m. EDT

- 231 The ABCs of thyroid cancer: Explaining key terms, concepts, and initial diagnostic and treatment steps.** Sarika N. Rao, DO, Endocrinologist. [SR]
- 232 Thyroid cancer imaging update: Ultrasound, CT, MRI, whole body scan, or PET/CT.** Robert Flavell, MD, PhD, Nuclear Medicine Physician. [SR]
- 233 Medullary thyroid cancer: How to monitor it with lab results and imaging; the location of the most common metastases, and how to find them.** Whitney S. Goldner, MD, Endocrinologist. [M,SR]
- 234 Pediatric thyroid cancer roundtable: Coping, treatment options, and being part of a community of survivors.** Carol DiFelice and Pam Mendenhall, LISW, ThyCa Volunteers. [Ped]
- 235 Overview and discussion about thyroid cancer and pregnancy.** Elizabeth N. Pearce, MD, MSc, Endocrinologist. [SR]

1:00 – 2:00 p.m. EDT

- 241 Controversies in thyroglobulin and thyroglobulin antibodies lab results.** Jonathan S. LoPresti, MD, PhD, Endocrinologist; and Carole A. Spencer, PhD, FACB, Professor of Medicine. [Adv,AYA,H,N,Ped,PF,SR]
- 242 Discuss the low-iodine diet with a dietitian.** Ashley Kratovil, RDN, Dietitian. [Adv,AYA,N,Ped,PF,SR]
- 243 Panel discussion: Updates from the Medullary Thyroid Cancer and MEN2 Registry.** Ruth A. Amaku, MPH, Senior Research Coordinator; Jessica Foft, Clinical Research Coordinator; Chelsea Herholdt, Clinical Research Coordinator; and Julie Ann Sosa, MD, MA, Surgeon. [M,SR]
- 244 Panel discussion: Pediatric thyroid cancer session 1. [Ped,SR]**
- **What tumor genetics tells us, and doesn't tell us, and how it relates to the patient.** Aime T. Franco, PhD, AYA Cancer Survivor.
 - **When should families worry about an inheritable risk for developing thyroid cancer?** Jonathan Wasserman, MD, PhD, Pediatric Endocrinologist.
- 245 Update on AYA thyroid cancer and discussion on friendships, dating, relationships, and how thyroid cancer affects them.** For people ages 18 to 40. Melanie Goldfarb, MD, Endocrine Surgeon.

2:30 – 3:30 p.m. EDT

- 251 The treatment(s) is/are over, what's next?** Johnny L. Rollins, APRN, ANP-C, Advanced Practice Provider.
- 252 A dietitian talks about diet and healthy eating.** Ashley Kratovil, RDN, Dietitian. [SR]
- 253 Medullary thyroid cancer: An open forum for discussion and questions and answers with a surgeon.** Gary L. Clayman, DMD, MD, FACS, Thyroid Cancer Surgeon. [M]
- 254 Panel discussion: Pediatric thyroid cancer session 2. [Ped,SR]**
- **Children are not just small adults: An update on pediatric thyroid cancer and recurrent and persistent thyroid cancer: A surgeon's perspective.** Peter Angelos, MD, PhD, Endocrine Surgeon.
 - **Care in the community: Information you need to know to try to optimize care for your child as well as being a knowledgeable advocate for the next pediatric patient diagnosed with thyroid cancer.** Andrew J. Bauer, MD, FAAP, Pediatric Endocrinologist.
- 255 Tratamiento quirúrgico del cáncer de tiroides en español.** Carlos S. Duque, MD, Cirujano de Cabeza y Cuello. [SR]

Session Key (You are welcome to attend any session.)

A: Anaplastic	Adv: Advanced Disease	AYA: Adolescent/Young Adult	H: Hurthle Cell	M: Medullary
N: Newly Diagnosed	Ped: Pediatric	PF: Papillary/Follicular	SR: Session to be Recorded	

Saturday, October 23, 4:00 – 5:00 p.m. EDT

- 261 Targeted therapies for advanced thyroid cancers; patient expectations.** An overview of thyroid cancer care as it has evolved to today's new approved therapies, therapies in clinical trials and on the horizon as well as future therapies in development. Bryan R. Haugen, MD, Endocrinologist. [A,Adv,AYA,H,M,PF,SR]
- 262 Ultrasound in the management of thyroid cancer.** Salem Noureldine, MD, Endocrine Surgeon. [SR]
- 263 Medullary thyroid cancer roundtable: Breakout rooms by disease status to talk after hearing from some of the doctors.**
Karen Geisenberger, Bill Nelson, Kelley Pratt, and Florence Zysman, ThyCa Volunteers. [M]
- 264 Pediatric thyroid cancer session 3.** [Ped,SR]
- Ask a doctor your questions about pediatric thyroid cancer, from minimally invasive to advanced disease. Andrew J. Bauer, MD, FAAP, Pediatric Endocrinologist.
- 265 Roundtable: Discussion among adolescents and young adults.** For people ages 18 to 40.
Aime T. Franco, PhD, AYA Cancer Survivor. [AYA]

5:30 – 6:30 p.m. EDT

- 271 Is there a role for immunotherapy in thyroid cancer?** Bryan R. Haugen, MD, Endocrinologist. [A,Adv,AYA,H,M,PF,SR]
- 272 Yoga for cultivating ease and self-compassion.**
Alison Christiansen, LCSW, Kripalu Yoga teacher.
- 273 Importance of tumor testing. Three patient stories involving rare papillary thyroid cancer mutations (nTRK, RET-PTC and ALK).** Marcia S. Brose, MD, PhD, Oncologist; and Susan Spinosa, ThyCa Volunteer. [A,Adv,AYA,M,N,PF]
- 274 AYA roundtable: Self-care and thyroid cancer.** Bev McLaughlin, MA, Patient Navigator. [AYA]
- 275 Roundtable: Anaplastic thyroid cancer.** Cheri Lindle, MEd, ThyCa Volunteer. [A]

Support the 20th ThyCa Auction

Go to www.thyca.org/auction and help us raise much-needed funds for thyroid cancer research. The auction ends at 9 p.m. EDT tonight.

Session Key (You are welcome to attend any session.)

A: Anaplastic	Adv: Advanced Disease	AYA: Adolescent/Young Adult	H: Hurthle Cell	M: Medullary
N: Newly Diagnosed	Ped: Pediatric	PF: Papillary/Follicular	SR: Session to be Recorded	

Sunday, October 24, 2021

- All program times are EDT (New York City time)
- Your feedback is important! Please fill out the session evaluation survey at the end of each session.

10:00 – 11:00 a.m. EDT

- 301 Thyroid cancer management during COVID-19.** Toni Beninato, MD, Endocrine Surgeon; Claire E. Graves, MD, Endocrine Surgeon; and Carrie C. Lubitz, MD, MPH, Endocrine Surgeon. [SR]
- 302 The many mutations of papillary thyroid cancer and why they need to be identified.** Eric J. Sherman, MD, Oncologist. [Adv,AYA,PF,SR]
- 303 Medullary thyroid cancer roundtable: Questions as we begin day 3.** Karen Geisenberger, ThyCa Volunteer. [M]
- 304 ThyCa support group facilitators: current and prospective.** Abby Melendez, Director of Support Groups; and Theresa Wickerham, ThyCa Program Coordinator.
- 305 Roundtable on health promotion: Sharing experiences with diet, exercise, and other complementary approaches to well-being.** Aime T. Franco, PhD, AYA Cancer Survivor; and Cal Pierce, ThyCa Volunteer.

11:10 – 11:20 a.m. EDT

- 316 Welcome and announcements.** Gary Bloom, ThyCa Executive Director; and Howard Solomon, ThyCa Board Chair.

11:30 a.m. – 12:30 p.m. EDT

- 321 Panel discussion: Thyroid hormone.** Antonio Bianco, MD, PhD, Endocrinologist; Francesco S. Celi, MD, Endocrinologist; Jacqueline Jonklaas, MD, PhD, MPH, Endocrinologist; and Lizzy McAninch, MD, Endocrinologist. [SR]
- 322 Test your cancer: Genomic cancer testing overview.** Shari Bates, BSN, RN, OCN, CCM; Catherine Shapple, MSN, RN; and Valentina D. Tarasova, MD, Endocrinologist. [A,Adv,AYA,H,M,N,PF,SR]
- 323 Medullary thyroid cancer: Update on medical management.** Ramona Dadu, MD, Endocrinologist. [M,SR]
- 324 Hurthle cell thyroid cancers – these are NOT papillary or follicular thyroid cancers.** Where is the research going in this disease and what has been done so far? David G. McFadden, MD, Endocrinologist. [Adv,AYA,H,SR]
- 325 Roundtable: Conquer the fear of cancer recurrence.** Theresa Wickerham, ThyCa Program Coordinator.

Session Key (You are welcome to attend any session.)

A: Anaplastic	Adv: Advanced Disease	AYA: Adolescent/Young Adult	H: Hurthle Cell	M: Medullary
N: Newly Diagnosed	Ped: Pediatric	PF: Papillary/Follicular	SR: Session to be Recorded	

Sunday, October 24, 1:00 – 2:00 p.m. EDT

331 What's on the horizon in thyroid cancer research. John A. Copland, III, PhD, Biologist.
[A,Adv,AYA,H,M,PF,SR]

332 Approaches for RAI therapy and RAI refractory (non-avid, RAI resistant) disease.
Mabel Ryder, MD, Endocrinologist. [Adv,H,PF,SR]

333 Medullary thyroid cancer: Does anyone have any more questions? What are you confused about? Harlan Perrins, ThyCa Volunteer. [M]

334 Surgical complications: Voice issues and other problems.
David Myssiorek, MD, FACS, Otolaryngologist. [SR]

335 Helping families communicate better with each other and with their medical team, including the value of emotional intelligence and the role of behavioral styles. Cheri Lindle, MEd, ThyCa Volunteer.

2:30 – 3:30 p.m. EDT

341 Panel discussion: Final question and answer session. We will address whatever questions have come up as the meeting has progressed.

Moderator: R. Michael Tuttle, MD, Endocrinologist.

Panelists: Carrie C. Lubitz, MD, MPH, Endocrine Surgeon; Mabel Ryder, MD, Endocrinologist; and Lori J. Wirth, MD, Medical Oncologist. [SR]

3:35 – 4:00 p.m. EDT

356 Conference wrap-up: Resources and next steps after the conference, your feedback on the conference, and suggestions for next year.

Gary Bloom, ThyCa Executive Director; and Theresa Wickerham, ThyCa Program Coordinator.

Thank you for attending! We hope to see you in person next year in Los Angeles, California!

Session Key (You are welcome to attend any session.)

A: Anaplastic	Adv: Advanced Disease	AYA: Adolescent/Young Adult	H: Hurthle Cell	M: Medullary
N: Newly Diagnosed	Ped: Pediatric	PF: Papillary/Follicular	SR: Session to be Recorded	
